Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects
- 1.2k Downloads
Salvinorin A is a kappa opioid agonist and the principal psychoactive constituent of the plant Salvia divinorum, which has increased in popularity as a recreational drug over the past decade. Few human studies have examined salvinorin A.
This double-blind, placebo-controlled study evaluated the dose-related effects of inhaled salvinorin A in individuals with histories of hallucinogen use.
Eight healthy hallucinogen-using adults inhaled up to 16 doses of salvinorin A (0.375–21 μg/kg) in ascending order. Physiological, behavioral, and subjective effects were assessed every 2 min for 60 min after administration. Qualitative subjective effects were assessed retrospectively via questionnaires at the end of sessions. Persisting effects were assessed 1 month later.
Orderly dose-related effects peaked at 2 min and then rapidly dissipated, replicating previous findings. Subjective effects were intense, with maximal drug strength ratings or unresponsiveness frequently observed at high doses. Questionnaires assessing qualitative effects (Hallucinogen Rating Scale, Pharmacological Class Questionnaire) suggested some overlap with serotonergically mediated classic hallucinogens. Salvinorin A also produced dose-related dissociative effects and impairments in recall/recognition memory. At 1-month follow-up, there was no evidence of persisting adverse effects. Participants reported that salvinorin A effects were qualitatively different from other drugs.
Salvinorin A produces a unique profile of subjective and cognitive effects, including strong dissociative effects and memory impairment, which only partially overlap with classic hallucinogen effects. Along with nonhuman studies of salvinorin A, these results are important for understanding the neurobiology of the kappa opioid system and may ultimately have important therapeutic applications.
KeywordsSalvinorin A Salvia divinorum Kappa opioid agonist Hallucinogen Psychedelic Dissociative Human
This work was supported by the National Institute on Drug Abuse (NIDA) through R01DA003889, T32DA007209, and R01DA018151. The authors would like to thank Annie Umbricht, M.D. and the medical staff at the Behavioral Pharmacology Research Unit for medical screening and medical coverage; Linda Felch for statistical analysis; Janna Bonesteel, Crystal Barnhouser, Eric Richter, Jenna Cohen, Samantha Gebhart, and Margaret Klinedinst for assistance in conducting sessions and collecting and organizing the data; Mary Cosimano, MSW, for conducting psychological screenings; and Ronald W. Wood, PhD for helpful discussions on drug volatilization.
Conflict of interest
All authors declare that they have no conflicts of interest.
- Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (2011) Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend 114:61–67. doi: 10.1016/j.drugalcdep.2010.09.006
- Beck AT, Steer RA, Brown GK (1996) Manual for the beck depression inventory-II. Psychological Corporation, San AntonioGoogle Scholar
- Derogatis LR (1993) BSI Brief Symptom Inventory: administration, scoring, and procedures manual. National Computer Systems, MinneapolisGoogle Scholar
- Fahn S, Tolosa E, Marín C (1993) Clinical rating scale for tremor. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Williams & Wilkins, Baltimore, pp 225–234Google Scholar
- Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S (1998) The anatomy of conscious vision: an fMRI study of visual hallucinations. Nature 1:738–742Google Scholar
- Isbell H, Bellevile RE, Fraser HF, Wikler A, Logan CR (1956) Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. Arch Gen Psychiatry 76:468–478Google Scholar
- Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115:150–155. doi: 10.1016/j.drugalcdep.2010.11.005
- McNair D, Lorr M, Droppleman L (1971) Manual for the profile of mood states. Education and industrial Testing Service, San DiegoGoogle Scholar
- Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET, Munro TA, Galloway GP, Cohen BM (2011) Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacol (Berl) 214:933–939. doi: 10.1007/s00213-010-2103-5 CrossRefGoogle Scholar
- Ott J (1995) Ethnopharmacognosy and human pharmacology of Salvia divinorum and salvinorin A. Curare 18:103–129Google Scholar
- Ott J (1996) Pharmacotheon: entheogenic drugs, their plant sources and history, 2nd edn. Natural Products Co., KennewickGoogle Scholar
- Ranganathan M, Schnakenburg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D’Souza DC (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist salvinorin A in humans. Biol Psychiatry 72:871–879. doi: 10.1016/j.biopsych.2012.06.012 PubMedCrossRefGoogle Scholar
- Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR (2012) High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacol (Berl). doi: 10.1007/s00213-012-2680-6
- Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Consulting Psychologist, Palo AltoGoogle Scholar
- Valdes 3rd LJ, Chang HM, Visger DC, Koreeda M (2001) Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum. Org Lett 3:3935–3937Google Scholar
- Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacol (Berl) 179:551–558. doi: 10.1007/s00213-004-2087-0 CrossRefGoogle Scholar